Product Information
DEXTROAMPH-AMPHET ER 37.5 MG CP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $8.2569 per EA under NDC 00480368501. Its NADAC has been published 115 times since Apr 17, 2024.
The High Outlier badge above means this manufacturer's average price in the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
DEXTROAMPH-AMPHET ER 37.5 MG CP
dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfateStrength
9.375; 9.375; 9.375; 9.375 mg/1; mg/1; mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00480368501
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
AMPHETAMINE ASPARTATE MONOHYDRATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210876On Market Since
10/10/2023
Pharmacological Classes
Price Statistics
The NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has been published 115 times since Apr 17, 2024, and over the history we have for it it has risen 4.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.2569 per EA |
|---|---|
| All-time high | $8.8791 (Jul 16, 2025) |
| All-time low | $7.7685 (May 22, 2024) |
| 52-week high | $8.8791 |
| 52-week low | $8.2569 |
| Median price | $8.4743 |
| Average price | $8.4596 |
| Largest weekly change | +10.9% (Jun 19, 2024) |
| Weeks tracked | 115 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of DEXTROAMPH-AMPHET ER 37.5 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DEXTROAMPH-AMPHET ER 37.5 MG CP, manufactured by Teva Pharmaceuticals USA Inc., is $8.2569 per EA (NDC 00480368501), effective Jun 24, 2026.
How has the price of DEXTROAMPH-AMPHET ER 37.5 MG CP changed over time?
Over the history we have for it, the NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has risen 4.7%. It has been tracked across 115 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DEXTROAMPH-AMPHET ER 37.5 MG CP?
Since Apr 17, 2024, the NADAC for DEXTROAMPH-AMPHET ER 37.5 MG CP has ranged from a low of $7.7685 (May 22, 2024) to a high of $8.8791 (Jul 16, 2025), with a median of $8.4743 per EA.
Are there cheaper alternatives to DEXTROAMPH-AMPHET ER 37.5 MG CP?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of DEXTROAMPH-AMPHET ER 37.5 MG CP, so no direct lower-cost alternative is listed.
Who manufactures DEXTROAMPH-AMPHET ER 37.5 MG CP?
DEXTROAMPH-AMPHET ER 37.5 MG CP (NDC 00480368501) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification